# LifeStance Health Group share price today (LifeStance Health Group, Inc., LFST)

> LifeStance Health Group, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. LFST · Healthcare · Medical Care Facilities · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/lfst

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $13.37 (+172.9% in a year)
- P/E: 103.8×, against its own history
- Revenue (Jun 2026): $435 M (+26.1% on a year ago)
- Profit (Jun 2026): $23.6 M
- Operating margin: 7.3% (+8.2 points on a year ago)
- ROE: 1%, FY25

Biggest thing to watch: margins are the best this company has ever reported. Every ratio looks better at a record, so the story depends on margins staying high. ## What is the LifeStance Health Group share price today? LifeStance Health Group, Inc.'s share price was $13.37 at the close on 3 November 2026. It has been rising for 26 weeks. That is 42.2% above its average price over the last 200 trading days. In the last 52 weeks it traded between $6 and $13, and at that close it was at the high of that range. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 3 weeks in a row. Over the last 5.4 years the share price moved −44% while the S&P 500 moved +78%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does LifeStance Health Group pay? LifeStance Health Group, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is LifeStance Health Group on? LifeStance Health Group is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is LifeStance Health Group profitable? LifeStance Health Group, Inc. earned $23.6 M of net profit in the Jun 2026 quarter. Full-year FY25 profit was $9.7 M. That is 5.4% of the quarter's revenue. The same quarter a year earlier lost $3.8 M. 7 of the last 12 reported quarters were loss-making. ## How much revenue does LifeStance Health Group make, and is it growing? LifeStance Health Group, Inc. reported $435 M of revenue in the Jun 2026 quarter, +26.1% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 4 years it has grown 20.9% a year on average. The last full year, FY25, came in at $1.4 B. The last four reported quarters add to $1.6 B. FY25 revenue was $1.4 B, +13.9% on the year before. Recent pace: the last four quarters grew +20.3% on average, against 20.9% a year over the longer run, so this year is growing at about the same pace as its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +20.4%, against +17.1% a year over the last 8 quarters (accelerating). ## How much of every $100 of sales does LifeStance Health Group keep? LifeStance Health Group, Inc.'s operating margin was 7.3% in the Jun 2026 quarter, 8.2 percentage points higher than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 5 years it has been between −42.5% and 1.8%. The latest quarter is above every full year in that period. Across 5 years it has been between −42.5% and 1.8%, and FY25's 1.8% is the highest of them. Why the margin moved: operating margin changed +8.2 percentage points on the year while gross margin changed +3.8 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. When margins are at a record, every ratio built on profit looks better than usual, so watch whether they hold. ## Is LifeStance Health Group's profit turning into cash? LifeStance Health Group, Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY25 it brought in $146 M of operating cash against $9.7 M of profit. After $36.1 M of spending on assets, $110 M was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does LifeStance Health Group's cash go? LifeStance Health Group, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $98.2 M on assets over the last 3 years. Averaged over those years that is 2.3% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $98.2 M over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is LifeStance Health Group's P/E ratio, and how does it compare with its own history? LifeStance Health Group, Inc.'s P/E is 103.8×, with too little history to compare. This compares the share price with the company’s own past. It does not say what the business is worth. In short: there is too little history to say whether the multiple is high or low for this company, so the earnings trend underneath matters more than the multiple. ## Is the LifeStance Health Group business getting better or worse? LifeStance Health Group, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. The latest quarter’s profit includes a one-off item bigger than the normal business, so the profit line is shown but does not count in this reading. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does LifeStance Health Group earn on its capital? LifeStance Health Group, Inc. earned a ROE of 1% in FY25. That is up from a low of −22% in FY21. Its return on capital used (ROIC) is 6.8 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a 0.7% net margin and 0.65× asset turnover (sales divided by assets). Why the return is what it is (FY25): a 0.7% net margin × 0.65× asset turnover × 1.45× leverage (assets divided by equity) ≈ 0.7% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 3.5% − 10.3% = −6.8 percentage points. The 10.3% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. The 3.5% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at 1.1%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does LifeStance Health Group have too much debt? LifeStance Health Group, Inc. has total debt of $474 M against shareholder equity of $1.5 B as of Jun 2026, so its debt is 0.32× its equity. Year by year, that ratio went from 0.10 in FY21 to 0.31 in FY25. Keep that borrowing in mind when reading the returns on this page. ## What is the LifeStance Health Group shareholding pattern? 4.7% of LifeStance Health Group, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so some traders are betting against it. At normal trading volumes, closing those positions would take about 3.0 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is LifeStance Health Group from balance-sheet trouble? For LifeStance Health Group, Inc., the Z-score is 2.53. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the grey area between the two. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 2.53 is in the grey area, neither clearly safe nor clearly in trouble. ## How does LifeStance Health Group rank in its industry? 55.7 out of 100, rank 12 of 30 in Medical Care Facilities, with 64% of the evidence available. LifeStance Health Group, Inc. scores 55.7 out of 100 against the 30 companies it is compared with in Medical Care Facilities, ranking 12. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 24.5 + 5.2 + 8.6 + 17.4 = 55.7. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is LifeStance Health Group compared with? LifeStance Health Group ranks 12 of 30 Medical Care Facilities companies on the 4-Factor Sector Score, with 55.7 out of 100. 1. [Concentra Group Holdings Parent, Inc.](https://www.sectoralpha.in/us/stocks/con) CON · leader · Most evidence points up · 81% evidence 71.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.4/35 · Revenue 14% · Profit 32.6% · Operating margin change 2.3 points · 83% evidence Capital efficiency 16.6/25 · ROCE 14.5% · Operating margin 19.3% · 76% evidence Valuation 13.0/20 · P/E 19.5× · PEG 0.65 · 65% evidence Relative strength 17.3/20 · Lead over its industry 18.3% · Lead over S&P 500 41.8% · 1 year 107.6% · 100% evidence · 12 of 12 weeks ahead Exact sum: 24.4 + 16.6 + 13 + 17.3 = 71.3 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Tenet Healthcare Corporation](https://www.sectoralpha.in/us/stocks/thc) THC · losing its lead · Evidence leans up · 81% evidence 64.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.0/35 · Revenue 5.4% · Profit 32.4% · Operating margin change 2.1 points · 83% evidence Capital efficiency 17.1/25 · ROCE 15% · Operating margin 18.2% · 76% evidence Valuation 15.3/20 · P/E 7.2× · PEG 0.35 · 65% evidence Relative strength 11.1/20 · Lead over its industry -3.8% · Lead over S&P 500 16.9% · 1 year 29.9% · 100% evidence · 11 of 12 weeks ahead Exact sum: 21 + 17.1 + 15.3 + 11.1 = 64.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. [AMN Healthcare Services, Inc.](https://www.sectoralpha.in/us/stocks/amn) AMN · breaking out · Evidence leans up · 64% evidence 64.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.3/35 · Revenue 23.9% · Profit n/a · Operating margin change 3.4 points · 62% evidence Capital efficiency 9.1/25 · ROCE 10.1% · Operating margin 4% · 76% evidence Valuation 10.4/20 · P/E 12× · PEG n/a · 15% evidence Relative strength 19.6/20 · Lead over its industry 37.8% · Lead over S&P 500 63.5% · 1 year 153.5% · 100% evidence · 9 of 12 weeks ahead Exact sum: 25.3 + 9.1 + 10.4 + 19.6 = 64.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Pediatrix Medical Group, Inc.](https://www.sectoralpha.in/us/stocks/md) MD · turning · Evidence leans up · 81% evidence 62.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.4/35 · Revenue 0.6% · Profit 61.5% · Operating margin change -0.2 points · 83% evidence Capital efficiency 14.6/25 · ROCE 14.8% · Operating margin 13.4% · 76% evidence Valuation 13.1/20 · P/E 11.6× · PEG 0.8 · 65% evidence Relative strength 15.2/20 · Lead over its industry 1.2% · Lead over S&P 500 23% · 1 year 39.5% · 100% evidence · 8 of 12 weeks ahead Exact sum: 19.4 + 14.6 + 13.1 + 15.2 = 62.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Healthcare Services Group, Inc.](https://www.sectoralpha.in/us/stocks/hcsg) HCSG · turning · Evidence leans up · 85% evidence 61.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.4/35 · Revenue 4% · Profit 100% · Operating margin change -3.2 points · 95% evidence Capital efficiency 14.5/25 · ROCE 17.7% · Operating margin 6.7% · 76% evidence Valuation 14.4/20 · P/E 13.4× · PEG 0.43 · 65% evidence Relative strength 12.6/20 · Lead over its industry -4.8% · Lead over S&P 500 15.9% · 1 year 48.1% · 100% evidence · 4 of 12 weeks ahead Exact sum: 20.4 + 14.5 + 14.4 + 12.6 = 61.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Encompass Health Corporation](https://www.sectoralpha.in/us/stocks/ehc) EHC · leader · Evidence leans up · 81% evidence 61.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.8/35 · Revenue 9.5% · Profit 20.2% · Operating margin change 0.3 points · 83% evidence Capital efficiency 18.1/25 · ROCE 17% · Operating margin 18.1% · 76% evidence Valuation 12.4/20 · P/E 16.2× · PEG 0.8 · 65% evidence Relative strength 12.9/20 · Lead over its industry -4.8% · Lead over S&P 500 16.2% · 1 year 16.9% · 100% evidence · 12 of 12 weeks ahead Exact sum: 17.8 + 18.1 + 12.4 + 12.9 = 61.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Nutex Health Inc.](https://www.sectoralpha.in/us/stocks/nutx) NUTX · leader · Evidence leans up · 64% evidence 60.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.5/35 · Revenue 6.8% · Profit 100% · Operating margin change 44 points · 62% evidence Capital efficiency 18.6/25 · ROCE 56.8% · Operating margin 57.8% · 76% evidence Valuation 10.9/20 · P/E 6.5× · PEG n/a · 15% evidence Relative strength 8.3/20 · Lead over its industry -5.5% · Lead over S&P 500 14.2% · 1 year 56.6% · 100% evidence · 12 of 12 weeks ahead Exact sum: 22.5 + 18.6 + 10.9 + 8.3 = 60.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Aveanna Healthcare Holdings Inc.](https://www.sectoralpha.in/us/stocks/avah) AVAH · leader · Too little evidence to rank firmly · 58% evidence 59.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 15.3/35 · Revenue n/a · Profit n/a · Operating margin change 1.6 points · 45% evidence Capital efficiency 15.3/25 · ROCE 17.7% · Operating margin 12.6% · 76% evidence Valuation 10.7/20 · P/E 7.2× · PEG n/a · 15% evidence Relative strength 18.2/20 · Lead over its industry 14.4% · Lead over S&P 500 37.9% · 1 year 51.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 15.3 + 15.3 + 10.7 + 18.2 = 59.5 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 9. [Addus HomeCare Corporation](https://www.sectoralpha.in/us/stocks/adus) ADUS · turning · Evidence leans up · 81% evidence 57.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.0/35 · Revenue 15.9% · Profit 27.7% · Operating margin change 0.3 points · 83% evidence Capital efficiency 12.9/25 · ROCE 11.4% · Operating margin 9.7% · 76% evidence Valuation 13.0/20 · P/E 17.4× · PEG 0.67 · 65% evidence Relative strength 10.7/20 · Lead over its industry -8.5% · Lead over S&P 500 11.9% · 1 year 11.9% · 100% evidence · 8 of 12 weeks ahead Exact sum: 21 + 12.9 + 13 + 10.7 = 57.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [HCA Healthcare, Inc.](https://www.sectoralpha.in/us/stocks/hca) HCA · breaking out · Evidence leans up · 81% evidence 57.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 15.8/35 · Revenue 7.3% · Profit 14.6% · Operating margin change -0.7 points · 83% evidence Capital efficiency 19.9/25 · ROCE 26.3% · Operating margin 15.2% · 76% evidence Valuation 14.3/20 · P/E 12.6× · PEG 0.49 · 65% evidence Relative strength 7.2/20 · Lead over its industry -21.2% · Lead over S&P 500 -2.7% · 1 year -2.9% · 100% evidence · 10 of 12 weeks ahead Exact sum: 15.8 + 19.9 + 14.3 + 7.2 = 57.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 11. [Universal Health Services, Inc.](https://www.sectoralpha.in/us/stocks/uhs) UHS · losing its lead · Evidence leans up · 81% evidence 56.3 out of 100 Growth Capital Valuation Relative
12. LifeStance Health Group, Inc. this page LFST · turning · Evidence leans up · 64% evidence 55.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.5/35 · Revenue 20.4% · Profit n/a · Operating margin change 8.1 points · 62% evidence Capital efficiency 5.2/25 · ROCE 4.2% · Operating margin 7.2% · 76% evidence Valuation 8.6/20 · P/E 82.1× · PEG n/a · 15% evidence Relative strength 17.4/20 · Lead over its industry 20.5% · Lead over S&P 500 44% · 1 year 112.6% · 100% evidence · 10 of 12 weeks ahead Exact sum: 24.5 + 5.2 + 8.6 + 17.4 = 55.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 13. [National HealthCare Corporation](https://www.sectoralpha.in/us/stocks/nhc) NHC · quiet · Evidence leans up · 81% evidence 54.0 out of 100 Growth Capital Valuation Relative
14. [PACS Group, Inc.](https://www.sectoralpha.in/us/stocks/pacs) PACS · quiet · Evidence leans up · 71% evidence 53.7 out of 100 Growth Capital Valuation Relative
15. [Fresenius Medical Care AG](https://www.sectoralpha.in/us/stocks/fms) FMS · basing · Evidence leans up · 81% evidence 50.7 out of 100 Growth Capital Valuation Relative
16. [Chemed Corporation](https://www.sectoralpha.in/us/stocks/che) CHE · quiet · Evidence leans down · 81% evidence 49.5 out of 100 Growth Capital Valuation Relative
17. [Guardian Pharmacy Services, Inc.](https://www.sectoralpha.in/us/stocks/grdn) GRDN · quiet · Evidence leans down · 64% evidence 49.3 out of 100 Growth Capital Valuation Relative
18. [Surgery Partners, Inc.](https://www.sectoralpha.in/us/stocks/sgry) SGRY · turning · Evidence leans down · 64% evidence 48.8 out of 100 Growth Capital Valuation Relative
19. [DaVita Inc.](https://www.sectoralpha.in/us/stocks/dva) DVA · turning · Evidence leans down · 81% evidence 47.6 out of 100 Growth Capital Valuation Relative
20. [Astrana Health, Inc.](https://www.sectoralpha.in/us/stocks/asth) ASTH · turning · Evidence leans down · 81% evidence 47.3 out of 100 Growth Capital Valuation Relative
21. [The Pennant Group, Inc.](https://www.sectoralpha.in/us/stocks/pntg) PNTG · turning · Evidence leans down · 81% evidence 43.9 out of 100 Growth Capital Valuation Relative
22. [The Ensign Group, Inc.](https://www.sectoralpha.in/us/stocks/ensg) ENSG · turning · Evidence leans down · 81% evidence 43.0 out of 100 Growth Capital Valuation Relative
23. [agilon health, inc.](https://www.sectoralpha.in/us/stocks/agl) AGL · quiet · Evidence leans down · 64% evidence 41.2 out of 100 Growth Capital Valuation Relative
24. [Option Care Health, Inc.](https://www.sectoralpha.in/us/stocks/opch) OPCH · breaking out · Evidence leans down · 81% evidence 41.0 out of 100 Growth Capital Valuation Relative
25. [Acadia Healthcare Company, Inc.](https://www.sectoralpha.in/us/stocks/achc) ACHC · quiet · Evidence leans down · 71% evidence 37.5 out of 100 Growth Capital Valuation Relative
26. [U.S. Physical Therapy, Inc.](https://www.sectoralpha.in/us/stocks/usph) USPH · leader · Evidence leans down · 81% evidence 36.3 out of 100 Growth Capital Valuation Relative
27. [Sonida Senior Living, Inc.](https://www.sectoralpha.in/us/stocks/snda) SNDA · basing · Evidence leans down · 64% evidence 36.2 out of 100 Growth Capital Valuation Relative
28. [Ardent Health, Inc.](https://www.sectoralpha.in/us/stocks/ardt) ARDT · losing its lead · Evidence leans down · 71% evidence 35.7 out of 100 Growth Capital Valuation Relative
29. [Brookdale Senior Living Inc.](https://www.sectoralpha.in/us/stocks/bkd) BKD · quiet · Most evidence points down · 64% evidence 32.8 out of 100 Growth Capital Valuation Relative
30. [Select Medical Holdings Corporation](https://www.sectoralpha.in/us/stocks/sem) SEM · Too little evidence to rank firmly · 36% evidence 50.9 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led S&P 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Medical Care Facilities](https://www.sectoralpha.in/us/sectors/medical-care-facilities), all 30 compared on one page. ## Which companies are close to LifeStance Health Group in size? LifeStance Health Group is the 11th largest of 38 Medical Care Facilities companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: PACS Group, Inc., Chemed Corporation and Concentra Group Holdings Parent, Inc. Just below it: Option Care Health, Inc., National HealthCare Corporation and Surgery Partners, Inc. ### Medical Care Facilities companies close in size

1. [PACS Group, Inc.](https://www.sectoralpha.in/us/stocks/pacs) $7.4 billion
2. [Chemed Corporation](https://www.sectoralpha.in/us/stocks/che) $6.9 billion
3. [Concentra Group Holdings Parent, Inc.](https://www.sectoralpha.in/us/stocks/con) $5.1 billion
4. LifeStance Health Group, Inc. $5.1 billion
5. [Option Care Health, Inc.](https://www.sectoralpha.in/us/stocks/opch) $4.8 billion
6. [National HealthCare Corporation](https://www.sectoralpha.in/us/stocks/nhc) $3.2 billion
7. [Surgery Partners, Inc.](https://www.sectoralpha.in/us/stocks/sgry) $3 billion

[All 38 Medical Care Facilities companies, largest first](https://www.sectoralpha.in/us/sectors/medical-care-facilities#all-companies)

### Companies close in size in other industries

1. [PTC Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/ptct) $5.1 billion · Biotechnology
2. [Klarna Group plc](https://www.sectoralpha.in/us/stocks/klar) $5.1 billion · Credit Services
3. LifeStance Health Group, Inc. $5.1 billion
4. [Sotera Health Company](https://www.sectoralpha.in/us/stocks/shc) $5.1 billion · Diagnostics & Research
5. [Cavco Industries, Inc.](https://www.sectoralpha.in/us/stocks/cvco) $5.1 billion · Residential Construction

## What else do people ask about LifeStance Health Group? ### What were LifeStance Health Group's latest quarterly results? LifeStance Health Group, Inc. reported revenue of $435 M and net profit of $23.6 M for the Jun 2026 quarter. Earnings per share were $0.06. The operating margin was 7.3%, 8.2 percentage points higher than a year earlier (as of 3 November 2026). ### What is LifeStance Health Group's market cap? LifeStance Health Group, Inc.'s market capitalisation is $5.1 B at a stock price of $13.37. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is LifeStance Health Group performing? LifeStance Health Group, Inc.'s share price has been rising for 26 weeks. Over the past 13 weeks it has done better than the S&P 500, for 3 weeks running. This describes what the data did, not a rating (as of 3 November 2026). ### Will LifeStance Health Group's stock price go up? This page does not forecast LifeStance Health Group, Inc.'s stock price. What it shows instead: the stock price is $13.37, and it has been rising for 26 weeks. Nobody can reliably say which way a price will move, and this site does not try (as of 3 November 2026). ### Where is LifeStance Health Group in its business cycle? LifeStance Health Group, Inc.'s FY25 operating margin was 1.8%, against a 5-year range of −42.5% to 1.8%: the top of its range, a record year. When profit is at a record, every ratio looks better than usual, and the story depends on margins staying high. The latest quarter was 7.3%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the LifeStance Health Group story? Biggest thing to watch: margins are the best this company has ever reported. Every ratio looks better at a record, so the story depends on margins staying high. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is LifeStance Health Group a stock worth studying right now? What the numbers show: LifeStance Health Group, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). This is research, not advice. We’re not SEBI-registered.